BioCentury
ARTICLE | Finance

ASH and others

Investors' top names and milestones in 4Q16

October 3, 2016 7:00 AM UTC

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less coverage. For example, at least one buysider thinks there could be important inflection points at the World Muscle Society meeting that kicks off Wednesday.

Other investors expect to find value by seeking out companies working in diseases such as glaucoma and migraine, where innovations have been few and far between, or by taking another look at markets like HCV or hereditary angioedema that, according to conventional wisdom, offer little commercial upside. ...